Question 1

What does Prismatic Advisory do?

Accepted Answer

Prismatic Advisory is a senior-led biopharma consultancy for value, access, and evidence. It provides value strategy, evidence generation, and stakeholder engagement — pairing strategic judgment with hands-on analytical execution.

Question 2

Who does Prismatic Advisory work with?

Accepted Answer

Prismatic works most often with HEOR, market access, value & access, and real-world evidence teams at biopharma companies, often in collaboration with medical affairs, commercial, clinical development, and patient-focused teams.

Question 3

What services does Prismatic Advisory offer?

Accepted Answer

Three core offerings: value strategy and differentiation (value, pricing, and competitive differentiation); evidence planning and generation (planning and generating evidence to fill key gaps); and stakeholder engagement (assessing stakeholder needs and publishing evidence for clear communication).

Question 4

Who leads the work at Prismatic Advisory?

Accepted Answer

Every engagement is led and executed by a senior consultant. Founder and principal John Jarvis brings 16 years of biopharma consulting experience across 50+ client organizations and 50+ treatment areas.

Question 5

When is Prismatic Advisory the right fit?

Accepted Answer

When you're making value, access, or evidence decisions and want a senior, hands-on partner; when the work benefits from both strategic thinking and analytical rigor; when direct stakeholder engagement (payers, providers, patients, caregivers) would strengthen the decision; and when you want a team that adapts to your priorities in real time.

Question 6

Does Prismatic Advisory conduct real-world evidence and health economic work?

Accepted Answer

Yes. The firm conducts and guides real-world data analyses, health economic modeling (cost-effectiveness and budget-impact), evidence gap assessments, and real-world evidence generation, and publishes peer-reviewed manuscripts, posters, and plain-language summaries.

Question 7

Can Prismatic Advisory assess whether a treatment is cost-effective?

Accepted Answer

Yes. Prismatic builds cost-effectiveness and budget-impact models and designs the analyses behind value-based pricing and HTA and payer submissions, pairing health economic rigor with the strategy to act on the findings.

A senior-led biopharma consultancyfor value, access, and evidence

A senior-led biopharma consultancy for value, access, and evidence

Value strategy, evidence generation, and stakeholder engagement for biopharma teams

Value strategy

Evidence generation

Stakeholder engagement

We help clients answer the following questions

Our work is guided by your business needs

Stakeholder decisions

Evidence assessment

Research and analysis

Communication

Why teams choose Prismatic

Senior led and executed

Broad experience

Strategic and analytical

Stakeholder-focused

Get in touch